



19th Executive Board
 Special Session on Proposals
 5 May 2014
 WHO, Geneva

Resolution n°4

Ensuring access to the HCV treatment revolution for HCV/HIV co-infected patients in Low and Middle Income Countries

Taking into account the outcome of the PRC review of 3-4 April 2014 and noting the issues raised for further clarification, the Executive Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to **USD 14 981 330** for the project *Ensuring access to the HCV treatment revolution for HCV/HIV co-infected patients in Low and Middle Income Countries*.

Description: The 3-year project plans to shape sustainable markets to ensure those living with HIV-HCV in low- and middle-income countries have rapid access to products for HCV, taking advantage of changes to the HCV landscape, including entry of directly-acting antivirals (DAAs) that are administered orally.

Lead organization(s): Médecins sans Frontières (Switzerland)

Consortium members: MSF France, Belgium and Holland; MSF Manson Unit, London; MSF Epicentre; School of Public Health, Imperial College, London; University of Bristol; London School of Hygiene and Tropical Medicine

Project duration: 3 years

Conditions for UNITAID funding support:

Funding is conditional upon:

- The development of a Project Plan to the satisfaction of the Secretariat, having regard to the issues raised by the PRC during its review.
- Review of the budget to ensure that all proposed costs are appropriate and reasonable (including with respect to any third-party recipients) to the satisfaction of the Secretariat.
- Signature of a legal agreement between Médecins sans Frontières (Switzerland) and UNITAID.

Philippe Douste-Blazy
 Chair of the UNITAID Executive Board